Misoprostol for Preventing Postpartum Hemorrhage

Completed 1200 enrolled Gynuity Health Projects Effective Care Research Unit · collab Family Care International · collab University of Witwatersrand, South Africa · collab

RandomizedParallel-groupTriple-blindPrevention

Summary

This hospital-based, multicenter, randomized, placebo-controlled trial will assess the effects of misoprostol as part of active management of the third stage of labor on postpartum blood loss, complications, and side effects. Twelve hundred eligible women will receive routine oxytocics (oxytocin 5-10 IU) plus either 400 mcg sublingual misoprostol or placebo during or immediately after delivery. The primary outcome will be measured blood loss of =\>500 mls within one hour after enrollment.

Timeline

Start: 2005-08
Primary completion: 2007-09
Completion: 2007-10

Publications

Hofmeyr GJ, Fawole B, Mugerwa K, Godi NP, Blignaut Q, Mangesi L, Singata M, Brady L, Blum J. Administration of 400 mug of misoprostol to augment routine active management of the third stage of labor. Int J Gynaecol Obstet. 2011 Feb;112(2):98-102. doi: 10.1016/j.ijgo.2010.08.019. Epub 2010 Dec 4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Misoprostol	Other / unclassified	400 ug	Other

Indications

No indication recorded.